FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005427839> ?p ?o ?g. }

• W2005427839 endingPage "425" @default.
• W2005427839 startingPage "420" @default.
• W2005427839 abstract "Background A definitive diagnosis of aspirin-exacerbated respiratory disease (AERD) requires a positive oral aspirin challenge (OAC), but predicting which patients will have positive challenges is often difficult. Objective To analyze information about historical aspirin- and nonsteroidal anti-inflammatory drug (NSAID)-associated respiratory reactions and clinical characteristics as potential markers to predict positive OACs. Methods A total of 243 patients underwent OACs. Data related to previous reactions and clinical characteristics of patients were correlated with the result of the OACs. Results Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks. Sex, atopy, number of sinus infections per year, and number of sinus surgical procedures were not associated with positive OACs. Patients with 2 or more prior aspirin- and NSAID-associated respiratory reactions had an 89% chance of having a positive OAC vs single reactors (80%; P = .04). Mild or moderate prior reactions were associated with 84% or 80% positive OACs, whereas 100% of the 45 patients with severe prior reactions had positive OACs (P = .007). Except for hospitalizations, treatment locations of prior reactions (home or emergency department) did not seem to make any difference. Logistic regression identified age, sense of smell, and multiple prior reactions as independent risk factors associated with positive OACs. Conclusions Age younger than 40 years, poor sense of smell, multiple prior respiratory reactions, and severe prior asthmatic reactions associated with aspirin and NSAIDs significantly increased the chances of a positive OAC. A definitive diagnosis of aspirin-exacerbated respiratory disease (AERD) requires a positive oral aspirin challenge (OAC), but predicting which patients will have positive challenges is often difficult. To analyze information about historical aspirin- and nonsteroidal anti-inflammatory drug (NSAID)-associated respiratory reactions and clinical characteristics as potential markers to predict positive OACs. A total of 243 patients underwent OACs. Data related to previous reactions and clinical characteristics of patients were correlated with the result of the OACs. Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks. Sex, atopy, number of sinus infections per year, and number of sinus surgical procedures were not associated with positive OACs. Patients with 2 or more prior aspirin- and NSAID-associated respiratory reactions had an 89% chance of having a positive OAC vs single reactors (80%; P = .04). Mild or moderate prior reactions were associated with 84% or 80% positive OACs, whereas 100% of the 45 patients with severe prior reactions had positive OACs (P = .007). Except for hospitalizations, treatment locations of prior reactions (home or emergency department) did not seem to make any difference. Logistic regression identified age, sense of smell, and multiple prior reactions as independent risk factors associated with positive OACs. Age younger than 40 years, poor sense of smell, multiple prior respiratory reactions, and severe prior asthmatic reactions associated with aspirin and NSAIDs significantly increased the chances of a positive OAC." @default.
• W2005427839 created "2016-06-24" @default.
• W2005427839 creator A5007991751 @default.
• W2005427839 creator A5019796172 @default.
• W2005427839 creator A5073256355 @default.
• W2005427839 creator A5080552142 @default.
• W2005427839 creator A5083729616 @default.
• W2005427839 date "2008-05-01" @default.
• W2005427839 modified "2023-10-02" @default.
• W2005427839 title "Predicting outcomes of oral aspirin challengesin patients with asthma, nasal polyps, andchronic sinusitis" @default.
• W2005427839 cites W1948059877 @default.
• W2005427839 cites W1996085958 @default.
• W2005427839 cites W2015130522 @default.
• W2005427839 cites W2018339880 @default.
• W2005427839 cites W2020636627 @default.
• W2005427839 cites W2050921420 @default.
• W2005427839 cites W2063737523 @default.
• W2005427839 cites W2064044682 @default.
• W2005427839 cites W2065610923 @default.
• W2005427839 cites W2075480456 @default.
• W2005427839 cites W2119753383 @default.
• W2005427839 cites W2131296354 @default.
• W2005427839 doi "https://doi.org/10.1016/s1081-1206(10)60465-6" @default.
• W2005427839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18517072" @default.
• W2005427839 hasPublicationYear "2008" @default.
• W2005427839 type Work @default.
• W2005427839 sameAs 2005427839 @default.
• W2005427839 citedByCount "105" @default.
• W2005427839 countsByYear W20054278392012 @default.
• W2005427839 countsByYear W20054278392013 @default.
• W2005427839 countsByYear W20054278392014 @default.
• W2005427839 countsByYear W20054278392015 @default.
• W2005427839 countsByYear W20054278392016 @default.
• W2005427839 countsByYear W20054278392017 @default.
• W2005427839 countsByYear W20054278392018 @default.
• W2005427839 countsByYear W20054278392019 @default.
• W2005427839 countsByYear W20054278392020 @default.
• W2005427839 countsByYear W20054278392021 @default.
• W2005427839 countsByYear W20054278392022 @default.
• W2005427839 countsByYear W20054278392023 @default.
• W2005427839 crossrefType "journal-article" @default.
• W2005427839 hasAuthorship W2005427839A5007991751 @default.
• W2005427839 hasAuthorship W2005427839A5019796172 @default.
• W2005427839 hasAuthorship W2005427839A5073256355 @default.
• W2005427839 hasAuthorship W2005427839A5080552142 @default.
• W2005427839 hasAuthorship W2005427839A5083729616 @default.
• W2005427839 hasConcept C126322002 @default.
• W2005427839 hasConcept C141071460 @default.
• W2005427839 hasConcept C151956035 @default.
• W2005427839 hasConcept C2776042228 @default.
• W2005427839 hasConcept C2777628954 @default.
• W2005427839 hasConcept C2777697326 @default.
• W2005427839 hasConcept C2777768476 @default.
• W2005427839 hasConcept C2781390199 @default.
• W2005427839 hasConcept C71924100 @default.
• W2005427839 hasConceptScore W2005427839C126322002 @default.
• W2005427839 hasConceptScore W2005427839C141071460 @default.
• W2005427839 hasConceptScore W2005427839C151956035 @default.
• W2005427839 hasConceptScore W2005427839C2776042228 @default.
• W2005427839 hasConceptScore W2005427839C2777628954 @default.
• W2005427839 hasConceptScore W2005427839C2777697326 @default.
• W2005427839 hasConceptScore W2005427839C2777768476 @default.
• W2005427839 hasConceptScore W2005427839C2781390199 @default.
• W2005427839 hasConceptScore W2005427839C71924100 @default.
• W2005427839 hasIssue "5" @default.
• W2005427839 hasLocation W20054278391 @default.
• W2005427839 hasLocation W20054278392 @default.
• W2005427839 hasOpenAccess W2005427839 @default.
• W2005427839 hasPrimaryLocation W20054278391 @default.
• W2005427839 hasRelatedWork W1943316663 @default.
• W2005427839 hasRelatedWork W2034176528 @default.
• W2005427839 hasRelatedWork W2096508268 @default.
• W2005427839 hasRelatedWork W2352748590 @default.
• W2005427839 hasRelatedWork W2406004019 @default.
• W2005427839 hasRelatedWork W2413350132 @default.
• W2005427839 hasRelatedWork W2425488977 @default.
• W2005427839 hasRelatedWork W2594220482 @default.
• W2005427839 hasRelatedWork W2981603615 @default.
• W2005427839 hasRelatedWork W4382940896 @default.
• W2005427839 hasVolume "100" @default.
• W2005427839 isParatext "false" @default.
• W2005427839 isRetracted "false" @default.
• W2005427839 magId "2005427839" @default.
• W2005427839 workType "article" @default.